Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment
AGN Neuro is also pleased to announce that as part of being appointed the CRO, Validcare has agreed to invest US $170K in exchange for equity issued by AGN Neuro. The investment in AGN Neuro will be ...
Nature3y
Psychedelic-assisted therapy: a new approach to treating depression
Small Pharma is the first company to conduct clinical trials to treat depression with the psychedelic N,N-dimethyltryptamine (DMT). “Combining pharmacological and psychological intervention is a ...
T-Net1d
Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial, Announces Validcare’s $250K Equity Investment
Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Validcare as ...